Roche Holding AG's Fiscal Year is From January To December - All Figures are in CHF, Billions.
The item "Total-Other-Finance-Cost" stands at -1.03 Billion Swiss Francs for the trailing twelve months (TTM) period ending 06/30/2025.
Roche Holding AG's second quarter result of 0.022 Billion CHF for the item "Total Other Finance Cost" represents an increase of 104.34 percent compared to it's first quarter result.
Also, Roche Holding AG's second quarter result of 0.022 Billion CHF for the item "Total Other Finance Cost" represents a decrease of -52.17 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Roche Holding AG's second quarter result of -1.03 Billion CHF for the item "Total Other Finance Cost" represents a decrease of -2.38 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.0761 Billion Swiss Francs compared to the value the year prior.
The 1 year change is -0.0761 Billion Swiss Francs.
The 3 year change is -1.43 Billion Swiss Francs.
The 5 year change is -0.2836 Billion Swiss Francs.
The 10 year change is 0.0986 Billion Swiss Francs.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Total Other Finance Cost | 905,699,262,464.00 |
![]() | Johnson & Johnson - Total Other Finance Cost | 486,508,953,600.00 |
![]() | AbbVie Inc - Total Other Finance Cost | 399,570,305,024.00 |
![]() | AstraZeneca PLC - Total Other Finance Cost | 280,205,508,085.11 |
![]() | Novartis AG - Total Other Finance Cost | 255,096,620,580.91 |